CPI to advance the development of regenerative medicine
Cobra Biologics Ltd (Cobra), international Contract Development and Manufacturing Organisation (CDMO) of biologics and pharmaceuticals, and the Centre for Process Innovation (CPI), a UK-based technology innovation centre, are collaborating on a project which will focus on the development of an industrial manufacturing platform for Adeno-Associated Virus (AAV) production to support gene therapy and regenerative medicine.
The collaboration, which is being led by Cobra, will focus on AAV vectors which are safe and effective and are currently the delivery vehicle of choice for gene therapy treatments. However, the advancement of these therapies into clinical trials is currently hampered by the lack of robust scalability needed to manufacture AAV vectors.
The proposed collaboration between Cobra and CPI will develop in depth scientific and technical understanding to allow a scalable and flexible manufacturing process to be developed to produce, purify and characterise a range of AAV vectors. This will enable the acceleration of more potential products into clinical testing and ultimately new medicines. This in turn will increase the chances of treatments being developed for a whole range of currently intractable diseases.
The £1.8M project is being funded to a value of £1.4M by Innovate UK via their 2015 competition for the development of regenerative medicines and cell therapies.
The project is one of five which together make up an £8 million government investment into collaborative R&D projects that address critical challenges faced by UK companies developing regenerative medicines and cell therapies as clinical treatments and commercial products.
The Centre for Process Innovation is a UK-based technology innovation centre and part of the High Value Manufacturing Catapult. We use applied knowledge in science and engineering combined with state of the art development facilities to enable our partners to develop, prove, prototype and scale up the next generation of products and processes.
Our open innovation model enables companies to develop products and prove processes with minimal risk. We provide assets and expertise so our partners can demonstrate the process before investing substantial amounts of money in capital equipment and training. New products and processes can be shown to be feasible; on paper, in the lab and in the plant before being manufactured at an industrial scale.
By utilising our proven assets and expertise companies can take their products and processes to market faster. There is no down time in production as all of the process development is completed offsite and our technology transfer and engineering teams can help companies to transfer the product or process into full scale production at speed.
About Cobra Biologics Ltd
Cobra Biologics is a leading international contract manufacturing organisation (CMO) of biologics and pharmaceuticals for clinical and commercial supply. Cobra has three GMP approved facilities, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract services, stretching from cell line and process development through to fill and finish for the supply of products for clinical trials and the commercial market.
We take pride in manufacturing excellence and being a trusted provider, delivering what we promise and helping our customers to develop medicines for the benefit of patients. Cobra supplies manufacturing solutions to the pharmaceutical industry covering antibodies, recombinant proteins, viruses, phage, DNA, microbiota vaccines and therapeutics as well as biologics and small molecule.
Let’s innovate together
To find out more about how we can work together, please enter your details below. More contact options